Ryman Healthcare Named New Zealand's Most Trusted Aged Care Brand
This marks the eleventh time Ryman has received the top industry award, reinforcing its long-standing reputation as New Zealand's most trusted and largest provider of retirement living and aged care.
Ryman Chief Executive Officer Naomi James says the award is a meaningful endorsement of the company's ongoing commitment to residents and their families.
'Care is at the heart of everything we do, and we appreciate the trust our residents and their families place in us to deliver on this commitment.'
Since 1984, Ryman has been guided by the belief that care should be 'good enough for Mum and Dad' - a principle that continues to inspire and unite the team 40 years on.
'I'm incredibly proud of our team,' says James. 'Their dedication, kindness, and the way they go the extra mile every day is what makes this recognition so meaningful. It's a true reflection of the care they show our residents, and their commitment to our purpose of delivering freedom, connection, and wellbeing as we grow older.'
Survey participants praised Ryman for its wonderful staff, excellent amenities, and the full range of care options offered across its villages, highlighting experiences of peace of mind for their loved ones. One participant noted:
'Ryman has been fantastic for my Nana. The staff are so caring and helpful.'
The annual Reader's Digest survey, conducted by Catalyst Consultancy & Research, asked 1,750 New Zealanders to select and rate the three brands they trust most across 66 different categories.
Ryman has won the top consumer award every year since 2014 aside from 2017 when it was highly commended.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
6 hours ago
- Scoop
OCR Cut Welcome For Some While Govt Leaves Many Behind
Poverty and homelessness continue to grow because of this Government's decisions, despite the Reserve Bank's move to lower the Official Cash Rate (OCR). 'The Reserve Bank's decision to lower interest rates today will be welcome news for some but won't help the thousands this Government has pushed into homelessness and poverty,' says Green Party co-leader and spokesperson for Finance Chlöe Swarbrick. 'Monetary policy is a blunt instrument. It is fiscal policy - that is, the Government's choices on tax and spend - which dictates who wins and who loses in our economy. 'While the OCR cut will provide some relief for those with a mortgage, the number of New Zealanders left out in the cold continues to grow under Luxon's decisions. Reports out today show families being forced to choose between unsafe boarding houses, or living on the street. 'Cuts to the OCR do not end poverty or homelessness, nor arrest growing inequality. The Government knows it can take action to address these problems, but is instead choosing to make them worse. 'While this Government tells people they're making the 'hard choices' to push more kids into poverty and increase emissions, the Greens will continue to fight for an Aotearoa where everyone thrives and nobody is left behind,' says Chlöe Swarbrick.
Scoop
6 hours ago
- Scoop
Pacific News In Brief For 20 August
Vanuatu - whooping cough The Vanuatu Daily Post is reporting the country's Ministry of Health has declared an outbreak of whooping cough. Over the past two weeks, the Ministry has recorded an increase in suspected cases. The paper reported that laboratory testing has confirmed that seven out of eight samples sent to the Victorian Infectious Diseases Reference Laboratory in Australia tested positive for Bordetella pertussis. All confirmed cases involved unvaccinated children under the age of five. West Papua - food A supplementary food programme has been launched for pregnant women and toddlers in West Papua. Indonesia's Antara news agency reports the collaboration between the Jayapura City Government in Papua and UNICEF aims to reduce stunting. Running from 2025 to 2026, the program will target nine priority health centres and posts. It will also include vitamin A distribution, routine growth monitoring, and the use of electronic data systems to track effectiveness. Papua New Guinea - flooding Food gardens in Bosset Village, in Papua New Guinea's Middle Fly District, have been severely damaged by three months of flooding. The Post-Courier reported the crops such as kaukau, cassava, and bananas have been affected, as well as sago, the staple food for Middle Fly communities. Flooding has swamped the sago areas, making harvesting difficult. The starch content has dropped and residents say it can take an entire day to find one suitable palm. Bosset Village has faced these challenges for years, often paddling long distances to neighboring areas such as Wangawanga and Aiambak to process sago. The Bosset community has conducted flood assessments and is now appealing to authorities and stakeholders for urgent assistance. Fiji - social media Fiji is looking at banning social media for under 16-year-olds, amid rising concerns over misinformation and online harm. The state broadcaster reported Communications Minister Manoa Kamikamica believes false content has contributed to youth suicide. Kamikamica said Fiji is in the early stages of reviewing social media laws, with potential restrictions and regulations likely to be debated within the next year. He said the Online Service Commission lacks clout and reforms will be considered alongside new legislation. Fiji - tourism Tourism in Fiji jumped 7.1 percent last month compared to July 2024. The Fiji Times reported Bureau of Statistics data showing there were 99,311 tourists for the month. Most visitors came for holidays or to visit family and friends, while a minority visited for business purposes. Australians made up the bulk of the tourists, followed by New Zealanders, Americans, Europeans and Chinese.
Scoop
7 hours ago
- Scoop
Cancer, Measles And Allergic Disease Research Funded In Latest HRC Grants Round
The Malaghan Institute has been awarded three Health Research Council grants, totalling $7.4M over five years, to improve cancer immunotherapies, protect vulnerable populations from measles outbreaks and investigate new therapeutic targets for eczema. Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institute's science. 'These investments not only reflect confidence in the Malaghan's research across cancer, allergic and infectious diseases, but also the real-world impact of our work on the health of New Zealanders.' Faster CARs: Overcoming exhaustion to enhance cancer immunotherapies Building on the Malaghan Institute's ground-breaking CAR T-cell programme, the Perret team in the Weinkove Laboratory has recieved a $1.2 million project grant over three years to improve on this life-saving treatment. 'In Aotearoa's first CAR T-cell trial, our novel CAR T-cell therapy has shown promising safety and efficacy in people with relapsed lymphomas,' says Dr Rachel Perret. 'However, a known limitation of CAR T-cell therapies is that in some cases, cancers fail to respond, or relapse. This may be due to exhaustion of CAR T-cells during manufacture or inside the patient, due to a immunosuppressive environment around the tumour.' Cells, like people, can become exhausted if overworked or overstimulated, becoming less and less able to perform. However, unlike people, CAR T-cells can be tweaked to block the genes that signal this exhaustion, allowing them to continue fighting cancer for longer – which should also improve patient outcomes. 'This project will re-engineer CAR T-cells to silence genes linked to exhaustion and re-develop CAR T-cell manufacturing processes to enhance CAR T- cell fitness and shorten manufacturing times,' says Dr Perret. 'We expect the results to be applicable to many cancer types, and to be readily translated for the benefit of New Zealanders within our CAR T-cell clinical trial programme.' Providing equal protection for everyone against measles Herd immunity is how we as a population protect those who are immunocompromised or otherwise unable to get vaccinated (such as very young infants) against potentially life-threatening viruses like measles. When enough of the population are vaccinated (over 95% in the case of measles), this herd immunity effectively prevents viruses from spreading to our most vulnerable whānau. 'While the current measles, mumps and rubella (MMR) vaccine is highly effective at protecting vaccinated individuals against these viruses, current vaccination rates are not high enough to provide this essential herd immunity to protect those who cannot be vaccinated,' says paediatric immunologist Dr Kuang Hsiao from Waipapa Taumata Rau, University of Auckland, who is part of the research team. The MMR vaccine cannot be used in people with severely impaired immune systems and is not recommended in pregnant people. Also, MMR is less effective in infants, so is not routinely recommended before 12 months of age. In addition, Māori and Pacific communities are overrepresented among these vulnerable groups. For these populations, alternate protective options are required to prevent a measles outbreak. 'Evidence has shown that mRNA-based vaccines can be effective in these vulnerable individuals,' says the Malaghan's Professor Ian Hermans. 'With an international team involving clinicians, immunologists and Māori and Pacific researchers, we will develop an mRNA-based measles vaccine to give to vulnerable individuals in the event of an outbreak.' The research has been awarded an HRC Programme Grant, worth $5M over five years, and will bring together multiple organisations including the Malaghan, representing diverse areas of expertise and combining both fundamental research and public health. 'As part of this work, we will explore with Māori and Pacific communities' perceptions and beliefs about mRNA-based vaccines to support equitable access to the vaccine,' says Dr Hermans. Investigating novel treatment targets for atopic dermatitis Atopic dermatitis, or eczema, is a chronic skin allergic disease that affects a significant proportion of New Zealand's population. The disease can have a significant negative impact on a person's livelihood with symptoms varying from persistent itchiness, redness, dryness and inflammation. Current treatment options are largely immunosuppressants such as corticosteroids, which can cause side effects. While these treatments can help manage symptoms there are currently no effective therapies to prevent the disease from developing and relapsing. At the cellular level, one hallmark of atopic dermatitis is the chronic infiltration and persistence of immune cells called tissue resident memory T-cells. Normally, these cells are vital for protecting the skin from invading pathogens, but for individuals with atopic dermatitis these cells also contribute to the disease by promoting recurring inflammation even after the allergen has been cleared from the skin. The project, which has been awarded $1.2 million over three years, will be led by Dr Sotaro Ochiai, a Senior Research Fellow in the Ronchese Laboratory. The team will focus on better understanding these tissue resident memory T-cells identifying key genes and biological pathways that are essential for the establishment and maintenance of these cells in the skin. 'By understanding these mechanisms, we aim to identify new therapeutic targets to disrupt tissue resident memory T-cell survival or function and improve quality of life for those affected by this persistent and distressing condition,' says Dr Ochiai.
